Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04278313 · ClinicalTrials.gov registry record · NA
Ovarian Function Following Intraovarian Injection of PRP
A NA study of Diminished Ovarian Reserve and Diminished Ovarian Reserve Due to Advanced Maternal Age, sponsored by Center for Human Reproduction.
- Active
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT04278313: Active NA study of Diminished Ovarian Reserve and Diminished Ovarian Reserve Due to Advanced Maternal Age, sponsored by Center for Human Reproduction.
NCT04278313 is a NA study of Diminished Ovarian Reserve and Diminished Ovarian Reserve Due to Advanced Maternal Age that is active but no longer recruiting, run by Center for Human Reproduction. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04278313, a NA study of Diminished Ovarian Reserve and Diminished Ovarian Reserve Due to Advanced Maternal Age, is active but no longer recruiting, sponsored by Center for Human Reproduction.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
Consenting women with evidence of poor ovarian reserve will be randomly assigned to treatment with either Platelet Rich Plasma (PRP) or Platelet Poor Plasma (PPP).
Primary Outcome
Number of participants with at least one day-3 embryo 8-cell with less than 5% fragmentation in an IVF cycle
Conditions Studied
Interventions
- PROCEDURE PRP - Platelet Rich Plasma
- PROCEDURE PPP - Platelet Poor Plasma
Study Locations (1)
New York
- Center for Human Reproduction - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2020-02-24 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What the registry record for NCT04278313 still lists
NCT04278313 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Diminished Ovarian Reserve appearing as the primary indexed condition, and to 2 interventions - of which PRP - Platelet Rich Plasma is the first listed.
NCT04278313 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04278313 about?
NCT04278313 is a clinical study titled "Ovarian Function Following Intraovarian Injection of PRP". Consenting women with evidence of poor ovarian reserve will be randomly assigned to treatment with either Platelet Rich Plasma (PRP) or Platelet Poor Plasma (PPP).
What is the current status of trial NCT04278313?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2020-02-24. Estimated completion is 2026-12-31.
What conditions does trial NCT04278313 study?
This clinical trial studies the following conditions: Diminished Ovarian Reserve, Diminished Ovarian Reserve Due to Advanced Maternal Age.
What interventions are being tested in trial NCT04278313?
The interventions under investigation include: PRP - Platelet Rich Plasma (PROCEDURE), PPP - Platelet Poor Plasma (PROCEDURE).
Who is sponsoring clinical trial NCT04278313?
This trial is sponsored by Center for Human Reproduction, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04278313 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diminished Ovarian Reserve
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04278313's enrollment target sits among peer trials
90 941st of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI